P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels

[1]  Weijian Huang,et al.  Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF-κB and P2X7R Signaling in PMA-Induced Macrophages , 2016, Front. Pharmacol..

[2]  S. Offermanns,et al.  Lineage tracing of cells involved in atherosclerosis. , 2016, Atherosclerosis.

[3]  P. Eriksson,et al.  NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis , 2016, Journal of the American Heart Association.

[4]  P. Pelegrín,et al.  Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process , 2016, Scientific Reports.

[5]  Herbert Zimmermann.  Extracellular ATP and other nucleotides—ubiquitous triggers of intercellular messenger release , 2015, Purinergic Signalling.

[6]  P. Qu,et al.  Expression of the NLRP3 Inflammasome in Carotid Atherosclerosis. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[7]  V. Lagente,et al.  ILr1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  F. Di Virgilio,et al.  The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Jason L Johnson,et al.  Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential , 2014 .

[10]  O. Alfieri,et al.  P467P2X7-MMP9 pathway in atherosclerosis: set up and characterization of ex-vivo and in vitro human vascular models , 2014 .

[11]  L. Stokes,et al.  The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease , 2014, Pharmacological Reviews.

[12]  S. Ryter,et al.  Inflammasomes: Molecular Regulation and Implications for Metabolic and Cognitive Diseases , 2014, Molecules and cells.

[13]  F. Mach,et al.  Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-κB Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis , 2014, Mediators of inflammation.

[14]  O. Alfieri,et al.  P2X7 receptor is expressed in human vessels and might play a role in atherosclerosis. , 2013, International journal of cardiology.

[15]  R. Webb,et al.  P2X7 receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction. , 2013, Clinical science.

[16]  X. Yuan,et al.  Melatonin inhibits IL1β-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NF-κB activation. , 2012, The Journal of endocrinology.

[17]  Gomez-Huelgas Ricardo,et al.  Alterations of specific biomarkers of metabolic pathways in vascular tree from patients with Type 2 diabetes , 2012, Cardiovascular Diabetology.

[18]  G. Owens,et al.  Smooth muscle cell phenotypic switching in atherosclerosis. , 2012, Cardiovascular research.

[19]  G. Owens,et al.  Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. , 2012, The Journal of clinical investigation.

[20]  R. Khalil,et al.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. , 2012, Experientia supplementum.

[21]  A. Nègre-Salvayre,et al.  A Key Role for Matrix Metalloproteinases and Neutral Sphingomyelinase-2 in Transplant Vasculopathy Triggered by Anti-HLA Antibody , 2011, Circulation.

[22]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[23]  R. Unwin,et al.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases , 2011, Expert opinion on investigational drugs.

[24]  C. Dinarello.  A clinical perspective of IL‐1β as the gatekeeper of inflammation , 2011, European journal of immunology.

[25]  D. Magne,et al.  Do cytokines induce vascular calcification by the mere stimulation of TNAP activity? , 2010, Medical hypotheses.

[26]  F. Di Virgilio,et al.  Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  C. Eder.  Mechanisms of interleukin-1beta release. , 2009, Immunobiology.

[28]  A. Newby.  Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[29]  O. Alfieri,et al.  Mild inflammatory activation of mammary arteries in patients with acute coronary syndromes. , 2008, American journal of physiology. Heart and circulatory physiology.

[30]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[31]  Chih‐Chung Lin,et al.  Interleukin‐1β induces MMP‐9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor‐κB signaling pathways in human tracheal smooth muscle cells , 2007 .

[32]  Chih‐Chung Lin,et al.  Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. , 2007, Journal of cellular physiology.

[33]  D. Donnelly-roberts,et al.  A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[34]  J. Wiley,et al.  Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. , 2006, Blood.

[35]  F. Di Virgilio,et al.  The P2X7 Receptor: A Key Player in IL-1 Processing and Release1 , 2006, The Journal of Immunology.

[36]  V. Dixit,et al.  Cryopyrin activates the inflammasome in response to toxins and ATP , 2006, Nature.

[37]  E. Raines,et al.  Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. , 2005, The Journal of clinical investigation.

[38]  Richard T. Lee,et al.  Smoking, Metalloproteinases, and Vascular Disease , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[39]  S. Greenfeder,et al.  Identification and characterization of splice variants of the human P2X7 ATP channel. , 2005, Biochemical and biophysical research communications.

[40]  M. Fishbein,et al.  Smoking Increases Inflammation and Metalloproteinase Expression in Human Carotid Atherosclerotic Plaques , 2004, Journal of cardiovascular pharmacology and therapeutics.

[41]  A. Ergul,et al.  Native matrix metalloproteinase characteristics may influence early stenosis of venous versus arterial coronary artery bypass grafting conduits. , 2004, Chest.

[42]  J. Paramo,et al.  Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. , 2003, Atherosclerosis.

[43]  M. Slater,et al.  Purinergic receptor distribution in endothelial cells in blood vessels: a basis for selection of coronary artery grafts. , 2002, Atherosclerosis.

[44]  F. Virgilio,et al.  P2 receptors: new potential players in atherosclerosis , 2002, British journal of pharmacology.

[45]  R. V. Sharma,et al.  Role of reactive oxygen species in IL-1 beta-stimulated sustained ERK activation and MMP-9 induction. , 2001, American journal of physiology. Heart and circulatory physiology.

[46]  K. Porter,et al.  Marimastat inhibits neointimal thickening in a model of human arterial intimal hyperplasia. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[47]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[48]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[49]  P. Libby,et al.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. , 1998, Journal of immunology.

[50]  HighWire Press,et al.  The journal of pharmacology and experimental therapeutics , 1909 .